Back to top
more

Esperion Therapeutics, Inc. (ESPR)

(Delayed Data from NSDQ)

$27.68 USD

27.68
552,296

-0.87 (-3.05%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (195 out of 253)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue

Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More

Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.

Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down

Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.

Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger

Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.78% and 4.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Esperion Therapeutics (ESPR) Q3 Earnings Expected to Decline

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion Therapeutics (ESPR) Up 12.6% Since Last Earnings Report: Can It Continue?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.

Esperion Therapeutics (ESPR) Beats Q2 Earnings Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy

Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates

Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 9.55% and 91.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Tilray (TLRY) in Focus: Stock Moves 9.6% Higher

Tilray (TLRY) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Esperion's Cholesterol Drugs Receive Approval in Europe

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.

Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates

Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 16.61% and 1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion's Promising Drugs Under Review, Funds a Concern

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.

Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%

Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -25.37% and 5.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?